Shots:

• Alkermes acquires Rodin in all cash transaction- making the total deal value as $950M which include $100M upfront in cash and up to $850M as clinical- regulatory and commercial milestones. The transaction is expected to be completed by the end of Nov’2019
• The acquisition will lead to the expansion of Alkermes’ Presence in CNS to a wide range of neurodegenerative disorders by leveraging Rodin’s synaptogenic platform
• Alkermes plans to advance IND activities for Rodin’s preclinical portfolio- prioritizing its clinical candidates and intends to continue Rodin’s preclinical research program focusing the subset of frontotemporal dementia patients with an inherited mutation of the progranulin gene (FTD-GRN) along with its work in hematology & oncology

Click here to­ read full press release/ article | Ref: Rodin Therapeutics  | Image: Business Wire